首頁 > 市場調查報告書 > 醫療設備

整形外科生物材料

市場調查報告書

商品編碼

2126473

脫鈣骨基質市場：策略性洞察與預測（2026-2031年）

Demineralized Bone Matrix Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月18日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計脫礦骨基質市場將以 4.98% 的複合年成長率成長，從 2025 年的 12.24 億美元成長到 2031 年的 16.38 億美元。

脫礦骨基質（DBM）市場正經歷顯著的變革，其驅動力包括整形外科和脊椎手術中生物材料增強技術的模式轉移、退化性肌肉骨骼疾病盛行率的上升，以及對能夠降低自體骨移植併發症的移植材料日益成長的需求。這一市場演變的特點在於，人們認知到DBM產品能夠提供骨傳導支持並保留與骨癒合相關的天然生長因子。這使其成為脊椎融合手術、創傷治療和重組手術中自體骨移植的寶貴替代方案。先進的組織處理技術、產品配方創新和整合的整形外科產品組合的融合，使得更穩定、更俱生物活性且更便於手術的骨移植解決方案成為可能。脊椎融合手術、創傷融合、整形外科翻修手術和顎顏面重組是主要的數據點，其需求與手術數量的相關性高於與可自由支配的醫療費用支出的相關性。隨著人口老化和整形外科手術量的增加，目標患者群體不斷擴大，產品差異化也越來越依賴操作特性、生物性能以及對手術流程的適用性。市場正投入大量資金用於產品標準化、臨床證據的累積以及與植入產品線的整合，脫鈣骨基質（DBM）正逐漸成為現代骨癒合策略中不可或缺的組成部分。

市場促進因素

脊椎融合手術手術數量的不斷成長是脫礦骨基質（DBM）市場的主要驅動力。椎間盤退化、脊椎狹窄、脊椎椎間滑脫和畸形矯正手術持續推高對骨移植材料的需求。由於從髂嵴取骨會增加手術時間和病患併發症的風險，外科醫師越來越傾向於尋找能夠減少自體骨取骨需求的移植材料。 DBM產品受益於此趨勢，因為它們無需額外的手術區域即可提供生物活性移植材料，從而推動了DBM使用量的持續成長。老化社會中肌肉骨骼疾病負擔的加重，透過擴大手術需求，進一步加速了市場成長。隨著人口老化，骨質疏鬆症、骨關節炎、脊椎疾病和骨折相關併發症的發生率不斷上升。這些疾病通常需要重組手術，而支持骨融合在臨床上至關重要。隨著醫療保健系統適應老年患者數量的成長，對骨再生產品的需求預計將繼續與整形外科手術數量的增加密切相關。在複雜的整形外科手術中，基於生物材料的增強療法日益受到青睞，這推動了專用脫鈣骨基質（DBM）配方的應用。外科醫師擴大在再次手術、多椎間脊椎融合手術以及骨癒合風險較高的困難創傷病例中使用生物材料。臨床實務正逐漸轉向將固定裝置與生物活性移植材料結合，以改善固定和癒合效果。門診整形外科手術的擴展增加了對易於獲取的DBM糊劑和凝膠的需求。成本控制措施和微創手術技術的改進導致在門診手術中心進行的整形外科手術數量增加。整形外科和脊椎相關企業的持續投資正在加強分銷網路，並為外科醫生提供更多獲取DBM產品的機會。

市場限制因素

對供體組織的依賴造成了供應限制。人源脫鈣骨基質（DBM）的生產依賴於透過組織庫網路取得供體骨，而供應量受捐贈率、篩檢要求、採集程序和加工能力的影響。骨誘導能力的差異會影響不同批次產品的一致性。供體特徵、加工技術、滅菌方法和儲存程序的差異會影響生物活性。組織衍生性商品的監管力道加大，導致營運成本上升，檢驗週期延長。人體組織產品在嚴格的法規結構下運營，該框架涵蓋供體合格、加工控制、可追溯性、儲存和上市後監測。與其他移植技術的競爭會限制DBM供應商的定價柔軟性。合成移植替代物、陶瓷材料、細胞骨基質和骨形成蛋白產品都在爭奪相同的適應症。保險報銷和成本壓力要求供應商既要證明其治療價值，又要證明其成本效益。

北美洲
- 依產品
- 材料
- 透過使用
- 最終用戶
- 國家
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 依產品
- 材料
- 透過使用
- 最終用戶
- 國家
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 依產品
- 材料
- 透過使用
- 最終用戶
- 國家
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 其他
中東和非洲
- 依產品
- 材料
- 透過使用
- 最終用戶
- 國家
  - 沙烏地阿拉伯
  - UAE
  - 其他
亞太地區
- 依產品
- 材料
- 透過使用
- 最終用戶
- 國家
  - 中國
  - 日本
  - 印度
  - 韓國
  - 台灣
  - 其他

第10章：競爭環境與分析

主要公司及策略分析
市佔率分析
合併、收購、協議和合作關係
競爭環境儀錶板

第11章：公司簡介

Medtronic plc
Zimmer Biomet Holdings, Inc.
Stryker Corporation
DePuy Synthes
Exactech, Inc.
SeaSpine Holdings Corporation
Straumann Group
NuVasive, Inc.

第12章附錄

簡介目錄

Product Code: KSI061616016

The Demineralized Bone Matrix Market is forecasted to grow at a 4.98% CAGR, increasing from USD 1.224 billion in 2025 to USD 1.638 billion in 2031.

The demineralized bone matrix market is undergoing significant transformation driven by the paradigm shift toward biologic augmentation in orthopedic and spinal procedures, the increasing prevalence of degenerative musculoskeletal disorders, and the growing demand for graft materials that reduce autograft harvesting morbidity. The market's evolution is characterized by the recognition that DBM products provide osteoconductive support and retain naturally occurring growth factors associated with bone healing, making them valuable alternatives to autograft in spinal fusion, trauma, and reconstructive procedures. The convergence of advanced tissue processing technologies, product formulation innovations, and integrated orthopedic portfolios is enabling more consistent, biologically active, and surgically convenient bone graft solutions. Spinal fusion surgeries, trauma fixation procedures, revision orthopedic operations, and maxillofacial reconstructions represent the primary sources of consumption, with demand closely tied to procedural volumes rather than discretionary healthcare spending. Aging populations and higher orthopedic surgery rates are expanding the addressable patient base, while product differentiation is increasingly based on handling characteristics, biological performance, and surgical workflow compatibility. The market is witnessing significant investment in product consistency, clinical evidence generation, and integration with implant portfolios, positioning DBM as a critical component of modern bone healing strategies.

Market Drivers

The increasing spinal fusion procedure volumes represent the primary driver for the demineralized bone matrix market. Degenerative disc disease, spinal stenosis, spondylolisthesis, and deformity correction procedures continue to generate demand for bone graft materials. Surgeons increasingly seek graft options that reduce the need for autologous bone harvesting because iliac crest harvesting can increase operative time and patient morbidity. DBM products benefit from this trend because they provide biologically active graft material without requiring a second surgical site, resulting in sustained growth in DBM utilization. The growing burden of musculoskeletal disorders among aging populations is further accelerating market growth through expanded procedural demand. Population aging is increasing the incidence of osteoporosis, degenerative joint disease, vertebral disorders, and fracture-related complications. These conditions frequently require reconstructive procedures where bone healing support is clinically important. As healthcare systems manage larger elderly patient populations, demand for bone regeneration products is expected to remain closely aligned with orthopedic procedural growth. Preference for biologic augmentation in complex orthopedic procedures is driving adoption of specialized DBM formulations. Surgeons increasingly use biologic materials in revision surgeries, multi-level spinal fusions, and challenging trauma cases where bone healing may be compromised. Clinical practice has gradually shifted toward combining fixation devices with biologically active graft materials to improve fusion and healing outcomes. The expansion of outpatient orthopedic surgery is increasing demand for ready-to-use DBM putties and gels. Ambulatory surgical centers are performing a growing number of orthopedic procedures due to cost containment initiatives and improvements in minimally invasive surgical techniques. Continued investment by orthopedic and spine companies is strengthening distribution reach and increasing surgeon exposure to DBM products.

Market Restraints

Dependence on donor tissue availability creates supply constraints. Human DBM production relies on donor bone procurement through tissue banking networks, with supply volumes influenced by donation rates, screening requirements, recovery procedures, and processing capacity. Variability in osteoinductive performance affects consistency across product lots. Differences in donor characteristics, processing techniques, sterilization methods, and preservation procedures can affect biological activity. Regulatory scrutiny of tissue-derived products increases operating costs and extends validation timelines. Human tissue products operate within stringent regulatory frameworks covering donor eligibility, processing controls, traceability, storage, and post-market surveillance. Competition from alternative graft technologies can limit pricing flexibility for DBM suppliers. Synthetic graft substitutes, ceramic-based materials, cellular bone matrices, and bone morphogenetic proteins compete for the same surgical indications. Reimbursement and cost pressures require suppliers to demonstrate both therapeutic value and cost effectiveness.

Technology and Product Insights

The technology landscape is characterized by the growing importance of product consistency, handling characteristics, and integration with surgical workflows. Spinal fusion represents the most commercially important application segment because the procedure requires successful bone formation between vertebral segments, making graft selection a critical component of clinical outcomes. Surgeons frequently use DBM as a graft extender or graft substitute because it offers osteoconductive support and retains naturally occurring growth factors associated with bone healing. Surgeons often prioritize fusion performance, graft handling properties, radiographic assessment compatibility, and ease of placement within confined anatomical spaces. Moldable putties and gels have gained acceptance because they simplify implantation and remain positioned at the surgical site during procedures. The segment analysis reveals that competition extends beyond traditional DBM products, with cellular allografts, synthetic graft substitutes, and recombinant growth factor technologies all targeting spinal fusion procedures. Suppliers increasingly emphasize clinical evidence, product consistency, surgeon training, and integration with spinal implant systems. Human-derived DBM remains the preferred material due to established clinical acceptance and regulatory familiarity. North America represents a mature market characterized by high procedural volumes, established tissue banking infrastructure, and widespread adoption of biologic graft materials. European demand is supported by aging populations, increasing prevalence of degenerative musculoskeletal disorders, and broad access to orthopedic care. Asia Pacific healthcare investment and expanding hospital networks are supporting demand. The integration of product formulation is becoming increasingly important as manufacturers expand DBM portfolios with specialized putties, gels, pastes, and moldable graft formats designed to improve ease of implantation across different surgical applications.

Competitive and Strategic Outlook

The competitive landscape combines multinational orthopedic manufacturers, spine specialists, tissue-processing organizations, and biologics suppliers, with market competition driven by product reliability, surgeon familiarity, regulatory compliance, distribution capabilities, and access to donor tissue resources rather than by price alone. Medtronic, Zimmer Biomet, Stryker, DePuy Synthes, SeaSpine, NuVasive, Exactech, and Straumann Group participate in adjacent orthopedic, spinal, and regenerative medicine segments that influence DBM demand. Many suppliers compete through bundled procedural solutions that combine implants, fixation systems, biologics, and surgical support services. Barriers to entry remain relatively high, with new participants required to establish donor sourcing capabilities, processing expertise, quality systems, regulatory compliance infrastructure, and surgeon relationships before achieving meaningful scale. Competitive differentiation increasingly centers on product consistency and biological performance, handling characteristics and ease of implantation, clinical evidence supporting fusion or healing outcomes, tissue sourcing and processing capabilities, regulatory compliance and traceability systems, and integration with broader orthopedic and spine portfolios. Recent key developments include Xtant Medical Holdings distributing HEMOBLAST Bellows, establishing a strong presence in the hemostatic and bone graft substitute sectors. Zimmer Biomet completed its acquisition of Paragon 28, strengthening its orthopedic reconstruction portfolio and expanding opportunities to integrate biologics into extremity procedures. Xtant Medical launched Trivium, a premium DBM allograft incorporating PureLoc Fiber Technology to provide interconnected porosity and superior biological activity. LifeNet Health unveiled PliaFX Flo, an injectable allograft that leverages a natural bone fiber formulation designed to optimize spinal fusion handling properties.

Short Conclusion

The demineralized bone matrix market is positioned for steady growth driven by the convergence of spinal procedure volumes, aging demographics, and biologic augmentation preferences. The transition from autograft harvesting toward ready-to-use biologic graft materials represents a fundamental shift in bone healing strategies. While challenges related to tissue availability, product variability, and regulatory compliance persist, strategic investments in processing capabilities, clinical evidence, and surgical integration are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with DBM evolving into a critical component of orthopedic and spinal procedures, supporting fusion success, bone healing, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DEMINERALIZED BONE MATRIX MARKET BY PRODUCT

5.1. Introduction
5.2. Gel
5.3. Putty
5.4. Paste
5.5. Graft
5.6. Others

6. DEMINERALIZED BONE MATRIX MARKET BY MATERIAL

6.1. Introduction
6.2. Human DBM
6.3. Animal DBM
6.4. Synthetic DBM

7. DEMINERALIZED BONE MATRIX MARKET BY APPLICATION

7.1. Introduction
7.2. Spinal Fusion
7.3. Dental / Maxillofacial Surgery
7.4. Trauma Surgery
7.5. Joint Reconstruction
7.6. Others

8. DEMINERALIZED BONE MATRIX MARKET BY END-USER

8.1. Introduction
8.2. Hospitals
8.3. Orthopedic Clinics
8.4. Ambulatory Surgical Centers
8.5. Others

9. DEMINERALIZED BONE MATRIX MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Product
- 9.2.2. By Material
- 9.2.3. By Application
- 9.2.4. By End-User
- 9.2.5. By Country
  - 9.2.5.1. USA
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. South America
- 9.3.1. By Product
- 9.3.2. By Material
- 9.3.3. By Application
- 9.3.4. By End-User
- 9.3.5. By Country
  - 9.3.5.1. Brazil
  - 9.3.5.2. Argentina
  - 9.3.5.3. Others
9.4. Europe
- 9.4.1. By Product
- 9.4.2. By Material
- 9.4.3. By Application
- 9.4.4. By End-User
- 9.4.5. By Country
  - 9.4.5.1. United Kingdom
  - 9.4.5.2. Germany
  - 9.4.5.3. France
  - 9.4.5.4. Spain
  - 9.4.5.5. Others
9.5. Middle East and Africa
- 9.5.1. By Product
- 9.5.2. By Material
- 9.5.3. By Application
- 9.5.4. By End-User
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
  - 9.5.5.2. UAE
  - 9.5.5.3. Others
9.6. Asia Pacific
- 9.6.1. By Product
- 9.6.2. By Material
- 9.6.3. By Application
- 9.6.4. By End-User
- 9.6.5. By Country
  - 9.6.5.1. China
  - 9.6.5.2. Japan
  - 9.6.5.3. India
  - 9.6.5.4. South Korea
  - 9.6.5.5. Taiwan
  - 9.6.5.6. Others